Digest Réseau Comment ça marche
Digest / Communiqué

RECORDATI: FDA GRANTS ISTURISA® (OSILODROSTAT) EXPANDED INDICATION FOR THE TREATMENT OF ENDOGENOUS HYPERCORTISOLEMIA IN PATIENTS WITH CUSHING’S SYNDROME

Compatibilité
Sauvegarder(0)
partager
RECORDATI: FDA GRANTS ISTURISA® (OSILODROSTAT) EXPANDED INDICATION FOR THE TREATMENT OF ENDOGENOUS HYPERCORTISOLEMIA IN PATIENTS WITH CUSHING’S SYNDROME
Documents joints (1)

216_153452_2025_oneinfo.pdf

Télécharger le dossier de presse ->
Coordonnées

Communiqués connexes

16/04/2025
Biotechnologie
Publicité/Marketing/Médias/Communication
Annonces Économiques
RECORDATI: FDA GRANTS ISTURISA® (OSILODROSTAT) EXPANDED INDICATION FOR THE TREATMENT OF ENDOGENOUS HYPERCORTISOLEMIA IN PATIENTS WITH CUSHING’S SYNDROME
Source
RECORDATI
Émetteur
GLOBENEWSWIRE
Découvrez les affinités
0
Press Release cover image
11/11/2025
Biotechnologie
Publicité/Marketing/Médias/Communication
Annonces Économiques
RECORDATI FIRST NINE MONTHS 2025 RESULTS: REVENUE +12.2%, EBITDA(1) +11.8%, ADJUSTED NET INCOME(2) +10.7%; ISTURISA PEAK SALES ESTIMATE DOUBLED TO GREATER THAN € 1.2 BILLION
Source
RECORDATI
Émetteur
GLOBENEWSWIRE
Découvrez les affinités
0
11/11/2025
Finance
Épargne/Affaires personnelles
Fonds d'investissement
Industrie
RECORDATI FIRST NINE MONTHS 2025 RESULTS: REVENUE +12.2%, EBITDA +11.8%, ADJUSTED NET INCOME +10.7%; ISTURISA PEAK SALES ESTIMATE DOUBLED TO GREATER THAN € 1.2 BILLION
Source
RECORDATI
Émetteur
1INFO
Découvrez les affinités
0